Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropath…

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy ...

A Quick Look at Today's Ratings for Vertex Pharmaceuticals (VRTX.US) with Forecasts Between $438 to $478

Stifel: Analyst Paul Matteis adjusts the target price from $494 to $445, maintaining a hold rating. This mixed bag of ratings illustrates the cautious optimism surrounding Vertex Pharmaceuticals, as ...

US$28.50: That's What Analysts Think Vertex, Inc. (NASDAQ:VERX) Is Worth After Its Latest Results

It's been a sad week for Vertex, Inc. ( NASDAQ:VERX ), who've watched their investment drop 14% to US$20.08 in the ...
Medscape

Consensus Report: Management of Type 1 Diabetes in Adults

A new consensus report on the management of type 1 diabetes in adults was presented recently at the European Association for ...

Vertex Reports Third Quarter 2025 Financial Results

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Vietnam Investment Review

Vietnamese fashion brand Coolmate secures Series C funding

Vietnamese fashion brand Coolmate has secured new funding to accelerate growth and expand its market presence.

Inflation-Proof Investing: Which Growth Stock Will Double Your Money in 6 Years?

Both companies are leaders in their niche with excellent growth prospects. They could deliver market-beating returns through ...